[1] Lou TW, Yang RX, Fan JG. The global burden of fatty liver disease: the major impact of China[J].Hepatobiliary Surg Nutr,2024,13:119-123. [2] 中华华医学会消化病学分会胃肠功能性疾病协作组与中华医学会消化病学分会胃肠动力学组, 2020年中国肠易激综合征专家共识意见[J]. 中华消化杂志, 2020. 40: 803-818. [3] Linsalata M, Riezzo G, Orlando A, et al. The role of intestinal barrier function in overweight patients with IBS with diarrhea undergoing a long-term low fermentable oligo-, Di-, and Monosaccharide and Polyol Diet[J].Nutrients,2023,15:4683.doi: 10.1186/s40360-018-0279-1. [4] Ng JJJ, Loo WM, Siah KTH. Associations between irritable bowel syndrome and non-alcoholic fatty liver disease: A systematic review[J]. World J Hepatol,2023,15:925-938. [5] Qiu YY, Zhang J, Zeng FY,et al. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)[J]. Pharmacol Res,2023,192: 106786. [6] Grabacka M, Płonka PM, Pierzchalska M. The PPARα regulation of the gut physiology in regard to interaction with microbiota, intestinal immunity, metabolism, and permeability[J].Int J Mol Sci, 2022, 23:14156. doi: 10.3390/ijms232214156 [7] Oka P, Parr H, Barberio B, et al. Global prevalence of irritable bowel syndrome according to Rome Ⅲ or Ⅳ criteria: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2020,5: 908-917. [8] Hung TH, Wang CY, Lee HF. Update in diagnosis and management of irritable bowel syndrome[J]. Tzu Chi Med J, 2023,35:306-311. [9] Black CJ, Staudacher HM, Ford AC. Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis[J]. Gut, 2022,71:1117-1126. [10] Inczefi O, Bacsur P, Resál T, et al. The influence of nutrition on intestinal permeability and the microbiome in health and disease[J]. Front Nutr, 2022,9:718710.doi:10.3389/fnut.2022.718710. [11] Xin D, Zong-Shun L, Bang-Mao W, et al. Expression of intestinal tight junction proteins in patients with non-alcoholic fatty liver disease[J]. Hepatogastroenterology, 2014, 61:136-140. [12] Quesada-Vazquez S, Bone C, Saha S, et al. Microbiota dysbiosis and gut barrier dysfunction associated with non-alcoholic fatty liver disease are modulated by a specific metabolic cofactors' combination[J]. Int J Mol Sci,2022,23:23.doi: 10.3390/ijms232213675. [13] Berthier A, Johanns M, Zummo FP, et al. PPARs in liver physiology[J]. Biochim Biophys Acta Mol Basis Dis, 2021,1867:166097.doi:10.3390/ijms232213675. [14] Decara J, Rivera P, López-Gambero AJ, et al.Peroxisome proliferator-activated receptors: experimental targeting for the treatment of inflammatory bowel diseases[J]. Front Pharmacol, 2020,11:730.doi:10.3389/fphar.2020.00730. [15] Pinna G. Role of PPAR-allopregnanolone signaling in behavioral and inflammatory gut-brain axis communications[J]. Biol Psychiatry,2023,94:609-618. [16] Zuo J, Ding Q, He S,et al. Hepatic cytochrome P450 8B1 and cholic acid potentiate intestinal epithelial injury in colitis by suppressing intestinal stem cell renewal[J]. Cell Stem Cell, 2022,29:1366-1381. |